Novo Holdings’ Assets Shrank As Novo Nordisk’s Value Sank
Novo Holdings’ annual report showed a -46.4% return on its Novo Nordisk shares in 2025 as the drugmaker struggled under the weight of competition. Its investment portfolio grew by 2.5%.
Scrip - March 12, 2026

BridgeBio Looks At Genetic Testing To Build Out BBP-418 Launch In LGMD2I/R9
The company presented updated data from the Phase III pivotal trial and plans to file for US FDA approval in the first half of the year.
Scrip - March 12, 2026

Execs On The Move: March 2–6, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - March 12, 2026

Highest WHO Acclaim For Singapore’s Regulation As IMDRF Profiles Global Playbook At 29th Meeting
IMDRF’s playbook on regulatory reliance was in the spotlight at the Forum’s 29th meeting this week, on the heels of its new midterm regulatory strategy document. 2026 IMDRF chair Singapore used the occasion to announce unprecedented WHO acclaim for the nation’s device regulatory oversight.
Medtech Insight - March 12, 2026

The Good, The Bad, And The Uncertainty: AI Diagnostic Dilemma Tops ECRI Patient Safety Concerns
As AI becomes ubiquitous in diagnosing diseases, clinicians must balance the technology’s enormous upside, such as improving the speed and accuracy of diagnoses, with the potential for errors that can lead to delayed or missed treatment.
Medtech Insight - March 12, 2026

SS Innovations Raises $18.6M To Fund US and EU Launch As FDA Decision Looms At Mid-2026
SS Innovations said the net proceeds from the financing will be directed toward working capital and general corporate purposes, with a focus on advancing global expansion efforts across existing and target markets.
Medtech Insight - March 12, 2026

Executives On The Move: Seven Firms Get New CFOs
Recent moves in the industry include C-suite changes at Syntis Bio, Inimmune and Epigenic Therapeutics, plus Seres Therapeutics gets a new interim CEO from Merck & Co.  
Scrip - March 12, 2026

Karo To Divest Locobase In Nordics To Win Approval For Perrigo Deal
Karo has come to an agreement with the Norwegian Competition Authority to sell its Locobase skin care brand to allay competition concerns in the Nordic region.
HBW Insight - March 12, 2026

Who’s Hired? Centrient Names Freeman To Replace Clements As CEO
Generics Bulletin brings you the most noteworthy recent appointments in the off-patent and value-added medicines space.
Generics Bulletin - March 12, 2026

FDA’s First PSG Batch Of 2026 Includes 98 Guidances
The US FDA released one of the highest numbers of product-specific guidances for generic development in a single batch.
Generics Bulletin - March 12, 2026

Almirall On The Lookout For More China Collaborations
The Spanish company has set up shop in Shanghai to be closer to current and future dermatology partners.
Scrip - March 12, 2026

Hikma Debuts Nucynta ER Rival In US
Hikma has introduced the first US rival to Nucynta ER in the form of a tapentadol extended-release authorized generic. The launch comes after the firm reported annual sales that were up but profits that were down, with new CEO Said Darwazah promising to right the ship.
Generics Bulletin - March 12, 2026

Podcast: Onchilles Pharma’s Neutrophil-Derived Path To Pan-Cancer Therapy
San Diego-based Onchilles Pharma's neutrophil-derived ELANE pathway agent N17350 targets a universal cancer vulnerability, combining direct tumor killing with immune activation. It is now entering first-in-human trials across solid tumors.
In Vivo - March 12, 2026

Samsung Bioepis Sharpens Differentiation Strategy As Global ADC Market Matures
In an interview with Scrip, Samsung Bioepis’ VP and Innovation Project Lead talks about the newly launched innovation project as well as the firm's strategies and goals in ADCs and other novel therapeutics.
Scrip - March 12, 2026

Estée Lauder Suit Against Walmart Renews Scrutiny Of Counterfeits Sold Online
Retailers selling third-party counterfeits online could be doing more to prevent the sale of the products, says an attorney.
HBW Insight - March 12, 2026

OTCs, Cosmetics In FDA’s Unified Adverse Event Monitoring Launch, Supplements Added In May
FDA launches first phase of unified platform for adverse event reports, replacing separate databases for different product types. Cosmetics, OTC drugs in initial launch; supplements start in May.
HBW Insight - March 12, 2026